infecti
diseas
still
repres
one
major
concern
human
veterinari
public
health
consequ
global
economi
due
climat
environment
chang
travel
trade
global
infecti
agent
spread
rapidli
wide
last
centuri
show
number
emerg
reemerg
viral
infect
appear
sinc
sever
acut
respiratori
syndrom
coronaviru
sarscov
middl
east
respiratori
syndrom
coronaviru
merscov
pandem
influenza
viru
wide
epidem
ebola
viru
ebov
west
africa
current
potenti
pandem
diffus
zika
viru
moreov
addit
zoonot
agent
identifi
caus
rare
potenti
lethal
infect
human
highli
pathogen
virus
mainli
belong
bunyavirida
crimeancongo
haemorrhag
fever
viru
rift
valley
viru
sever
hantavirus
flavivirida
dengu
west
nile
viru
arenavirida
lassa
viru
junin
viru
paramyxovirida
hendra
viru
nipah
viru
orthomyxovirida
avian
influenza
virus
due
sporad
outbreak
human
highli
pathogen
virus
requir
continu
surveil
activ
need
signific
effort
nation
health
system
intern
author
date
specif
drug
avail
treat
patient
infect
agent
belong
wide
array
emerg
reemerg
virus
thu
urgent
need
developmentvalid
effect
antivir
classic
approach
develop
antivir
drug
base
compound
affect
function
specif
viral
protein
play
key
role
viral
life
cycl
approach
use
success
instanc
control
human
immunodefici
viru
hiv
infect
inde
thank
avail
treatment
aid
becom
chronic
diseas
life
expect
peopl
live
hiv
significantli
increas
year
recent
follow
similar
approach
effect
drug
hepat
c
viru
hcv
develop
current
avail
antivir
drug
includ
compound
offici
approv
clinic
use
howev
number
human
health
threaten
virus
control
drug
less
situat
even
worst
case
neglect
viral
infect
whose
treatment
select
drug
expect
appear
market
near
futur
due
limit
busi
potenti
fact
usual
affect
popul
poor
socioeconom
background
final
virus
classifi
highli
pathogen
requir
biosafeti
level
facil
protocol
thu
render
drug
discoveri
develop
extrem
difficult
take
account
aspect
along
analysi
develop
specif
drug
viru
problem
select
drugresist
mutant
new
approach
focus
identif
broadspectrum
compound
target
mechan
allow
establish
infect
share
differ
virus
one
strategi
repres
developmentselect
compound
abl
affect
sever
virus
inhibit
common
viral
enzymat
function
first
exampl
drug
ribavirin
follow
recent
gener
new
nucleotid
nucleosid
analog
virus
oblig
intracellular
parasit
hijack
cellular
protein
membran
replic
cycl
exploit
sever
cellular
compon
allow
viral
entri
genom
replic
viral
particl
assemblybud
inde
agent
target
host
function
requir
infect
multipl
virus
absenc
signific
cytotox
could
repres
altern
way
develop
new
broadspectrum
antivir
therapi
particular
identif
commerci
avail
drug
alreadi
approv
use
human
activ
virus
might
acceler
organ
clinic
trial
eventu
clinic
use
especi
case
outbreak
highli
pathogen
virus
cation
amphiphil
drug
cad
wide
group
chemic
character
common
structur
featur
hydrophob
aromat
ring
ring
system
hydrophil
sidechain
contain
ioniz
amin
function
group
cad
includ
antidepress
antibiot
antipsychot
antimalari
antiarrhythm
cholesterollow
fertilityregul
drug
cad
propens
interact
differ
cell
membran
accumul
acid
intracellular
compart
late
endosomeslysosom
leli
cellular
uptak
mechan
markedli
differ
differ
cad
inde
accumul
ly
within
minut
hour
vitro
cell
exposit
differ
kinet
depend
chemicalphys
characterist
molecul
amin
function
group
compound
mainli
unproton
physiolog
ph
insid
acid
environ
leli
molecul
becom
proton
sinc
longer
permeat
membran
get
trap
insid
organel
figur
phdepend
partit
cad
result
pronounc
accumul
drug
lead
variou
physiolog
morpholog
alter
leli
compart
one
effect
observ
accumul
insid
leli
variou
lipid
speci
cholesterol
sphingomyelin
phosphatidylserin
phosphatidylethanolamin
phosphatidylcholin
bi
monoacylglycero
phosphat
bmp
induc
accumul
membran
structur
mark
expans
organel
volum
phenotyp
recal
one
observ
patient
niemann
pick
typec
npc
diseas
lipid
storag
disord
cad
show
induc
phospholipidosi
therapeut
relev
concentr
chronic
treatment
howev
cad
current
clinic
use
well
toler
lipid
accumul
associ
clear
cut
manner
clinic
consequ
furthermor
cell
chang
induc
cad
revers
rebound
effect
describ
associ
discontinu
cad
druginduc
phospholipidosi
believ
result
direct
interact
cad
membran
phospholipid
abil
specif
cad
induc
phospholipidosi
correl
posit
strength
drugphospholipid
interact
interact
cad
membran
modifi
permeabl
well
membraneproxim
ph
thu
affect
sever
biolog
process
particular
level
leli
inhibit
sever
enzymat
activ
chang
distribut
lysosom
enzym
acid
sphingomyelinas
asmas
lysosom
enzym
catalyz
hydrolysi
sphingomyelin
ceramid
phosphorylcolin
one
target
sever
cad
shown
antidepress
desipramin
relat
drug
induc
detach
asmas
inner
membran
leaflet
ly
consecut
inactiv
result
accumul
sphingomyelin
reduct
asmas
activ
also
report
two
cad
antiarrhythm
amiodaron
inhibitor
cholesterol
transport
furthermor
report
structur
differ
cad
addit
effect
inhibit
asmas
activ
argu
action
compound
molecular
target
interestingli
low
level
asmas
activ
detect
cell
patient
npc
diseas
underli
similar
cellular
phenotyp
observ
cell
npc
patient
individu
treat
cad
abil
cad
interact
biogenesi
lumin
acidif
leli
compart
may
affect
proteas
phospholipas
catepsin
could
explain
abil
amiodaron
inhibit
degrad
lung
surfact
protein
vitro
well
vivo
furthermor
shown
bepridil
antiarrhythm
drug
amiodaron
inhibit
activ
lysosom
betasecretas
differenti
modifi
specif
gammasecretas
cleav
amyloid
precursor
protein
note
cad
necessarili
interact
phospholipid
bilay
cellular
membran
exampl
antimalari
drug
chloroquin
interact
phospholipid
hand
interact
take
place
differ
featur
instanc
antipsychot
drug
chlorpromazin
aspecif
interact
membran
caus
increas
membran
permeabl
amiodaron
alter
lipid
dynam
interact
hydrophob
core
membran
bilay
differ
cad
behavior
give
reason
differ
abil
induc
phospholipidosi
cellular
metabol
alter
final
suggest
differ
cad
induc
cellular
phenotyp
target
specif
substrat
differ
mechan
action
inde
amiodaron
induc
npclike
phenotyp
format
enlarg
vacuol
enrich
bmp
cholesterol
remov
allevi
chang
bmp
distribut
induc
one
induc
amiodaron
suggest
differ
mechan
action
amiodaron
dronedaron
verapamil
ion
channel
blocker
use
control
supraventricular
ventricular
arrhythmia
recent
shown
molecul
inhibit
cell
entri
filovirus
particular
demonstr
amiodaron
main
metabolit
methyldiethanolamin
show
addit
effect
inhibit
ebov
entri
concentr
close
found
sera
patient
treat
arrhythmia
drug
act
interf
fusion
viral
envelop
endosom
membran
antivir
activ
correl
drug
abil
accumul
leli
compart
interfer
endocyt
pathway
vivo
posit
effect
amiodaron
also
partial
report
mous
model
signific
clinic
improv
report
human
treat
amiodaron
last
ebov
epidem
western
africa
interestingli
amiodaron
also
inhibit
infect
addit
virus
new
world
arenaviru
guanarito
sarscov
hcv
howev
virus
old
world
arenaviru
lassa
rhabdovirida
vesicular
stomat
viru
vsv
rabi
bunyavirida
hantaan
crimeancongo
hemorrhag
fever
viru
cchfv
dengu
inhibit
least
test
condit
vitro
strong
antivir
activ
ebov
also
report
calcium
channel
blocker
bepridil
abovedescrib
drug
bepridil
inhibit
step
follow
viral
intern
take
place
viral
fusion
furthermor
bepridil
display
also
signific
surviv
benefit
surviv
rate
mice
expos
ebola
viru
although
ion
channel
blocker
gener
inhibit
viral
infect
earli
stage
life
cycl
effect
amiodaron
verapamil
addit
step
viral
replic
follow
entri
phase
also
describ
instanc
case
hcv
amiodaron
affect
viral
entri
downregul
viral
receptor
cellular
membran
well
viral
assembl
via
suppress
microsom
triacylglycerol
transfer
protein
activ
verapamil
report
inhibit
egress
matur
sindbi
vesicular
stomat
virus
infect
cell
chloroquin
antimalari
drug
gradual
dismiss
antimalari
therapi
prophylaxi
due
emerg
resist
plasmodium
strain
shown
chloroquin
deriv
inhibit
vitro
replic
sever
virus
includ
hiv
sar
merscov
alphavirus
cchfv
dengu
zika
viru
japanes
enceph
viru
ebov
influenza
viru
caliciviru
herp
simplex
viru
furthermor
recent
report
chloroquin
inhibit
lytic
replic
latent
infect
epsteinbarr
viru
kaposi
sarcomaassoci
herpesviru
human
b
cell
clinic
accept
dose
mechan
action
chloroquin
multipl
depend
pathogen
like
act
increas
endosom
golgi
vesicl
ph
downregul
product
cytokin
express
receptor
thu
chloroquin
directli
inhibit
virus
requir
acid
ph
insid
leli
enter
cytosol
mitig
deleteri
effect
immun
activ
induc
certain
viral
infect
unfortun
vivo
evid
support
poorli
support
efficaci
chloroquin
treatment
hiv
dengu
ebov
influenza
two
clinic
trial
specif
aim
address
chloroquin
efficaci
acut
phase
chikungunya
viru
infect
conclud
contrast
result
hand
chloroquin
seem
effect
vivo
least
mous
model
inhibit
human
coronaviru
subtyp
ebov
well
aotu
monkey
affect
dengu
viru
type
replic
among
antimalari
drug
amodiaquin
deriv
along
quinacrin
mefloquin
shown
display
vitro
activ
flavivirus
wellknown
antipsychot
drug
chlorpromazin
report
antivir
activ
adenoviru
ebov
coronaviru
cchfv
chlorpromazin
known
interfer
format
clathrinco
pit
thu
would
act
inhibit
clathrinmedi
endocytosi
virion
case
cchfv
drug
shown
markedli
reduc
viral
titer
ad
post
infect
suggest
post
entri
inhibitori
effect
assembl
matur
viral
progeni
andor
exit
infect
cell
might
good
candid
alreadi
identifi
target
action
chlorpromazin
case
vesicular
stomat
viru
sindbi
viru
abil
inhibit
parvovir
entri
report
antidepress
desipramin
lipid
raftdisrupt
mechan
recent
carett
cowork
show
psychoact
drug
imipramin
interfer
entri
ebov
target
cell
similar
effect
report
differ
psychoact
drug
antidepress
drug
sertralin
trimipramin
well
antihistamineantiemet
drug
promethazin
furthermor
sertralin
report
inhibit
also
zika
viru
infect
screen
studi
drug
repurpos
antivir
show
serm
activ
merscov
ebov
hcv
antiebov
activ
serm
demonstr
even
absenc
detect
express
estrogen
receptor
suggest
clomiphen
toremifen
work
classic
pathway
associ
estrogen
receptor
function
instead
compound
would
interfer
late
stage
ebov
entri
target
cell
like
affect
trigger
fusion
viral
envelop
endosom
limit
membran
fact
recent
shown
toremifen
interact
ebov
glycoprotein
gp
trigger
prematur
releas
subunit
thu
prevent
fusion
process
clomiphen
toremifen
found
affect
ebov
infect
vitro
mous
model
interestingli
clomiphen
accumul
eye
male
reproduct
tract
ebov
known
persist
patient
recov
infect
thu
compound
would
potenti
act
also
ebov
reservoir
survivor
patient
sever
protein
kinas
involv
viral
traffick
entri
assembl
releas
infect
cell
shown
inhibitor
protein
kinas
use
approv
anticanc
drug
act
vitro
hcv
hiv
sever
flavivirus
ebov
particular
cad
sunitinib
inhibit
adapterassoci
kinas
cyclin
gassoci
kinas
requir
hcv
assembl
sunitinib
combin
anticanc
drug
erlotinib
protein
kinas
inhibitor
protect
mice
challeng
lethal
dose
ebov
dengu
other
kinas
inhibitor
use
cancer
treatment
broad
antivir
activ
last
larg
outbreak
ebov
west
africa
sever
paper
base
screen
studi
publish
effort
identifi
molecul
antiebov
activ
among
cad
shown
inhibit
ebov
infect
antifung
drug
terconazol
triparanol
formerli
use
cholesterollow
drug
withdrawn
due
numer
toxic
side
effect
among
cad
still
use
clinic
practic
deserv
consider
inde
cholesterol
synthesi
transport
inhibitor
wide
use
prototyp
cad
field
lipid
research
efficaci
test
import
human
relev
pathogen
dengu
viru
hbv
hcv
lujo
viru
ebov
well
develop
therapeut
intervent
prion
diseas
due
wellknown
effect
cell
employ
experi
led
identif
ebovintracellular
receptor
although
physic
interact
antiebov
activ
seem
independ
interact
like
due
pleiotrop
effect
leli
system
although
cad
wide
heterogen
group
chemic
share
common
chemicalphys
characterist
allow
cellular
accumul
acid
organel
induc
npclike
phenotyp
alter
sever
pathway
connect
endolysosom
compart
cellular
alter
affect
viral
replic
cycl
sever
virus
mainli
entri
step
case
also
level
viral
assemblybud
cad
effect
vitro
wide
number
virus
limit
vivo
studi
support
vitro
observ
howev
cad
seem
promis
tool
develop
broadrang
antivir
therapi
particular
control
outbreak
emerg
reemerg
highli
pathogen
virus
cad
inhibit
viral
replic
differ
unclarifi
mechan
understand
molecul
interfer
viral
replic
cycl
could
provid
basi
proper
evalu
therapeut
potenti
context
model
studi
evalu
possibl
interact
cad
cellularvir
protein
could
shed
light
complex
mechan
underli
cad
antivir
activ
respect
recent
studi
involv
molecular
model
suggest
amiodaron
dronedaron
well
toremifen
might
directli
interact
ebola
viru
surfac
glycoprotein
hand
least
case
amiodaron
studi
base
biolog
assay
indic
anti
ebov
drug
activ
limit
effect
viral
entri
also
due
effect
overal
cellular
physiolog
turn
influenc
viral
replic
taken
togeth
result
highlight
complex
antivir
mechan
cad
repurpos
clinic
approv
drug
antivir
appeal
good
safeti
data
exist
previou
clinic
studi
allow
faster
transit
phase
clinic
trial
addit
consid
cad
mainli
exert
antivir
activ
act
cellular
target
one
posit
aspect
repres
fact
develop
resist
viral
strain
unlik
although
numer
vitro
studi
vivo
evid
anim
model
suggest
possibl
employ
cad
antivir
use
deserv
consider
cad
requir
long
time
reach
tissu
plateau
concentr
human
tissu
compar
vitro
cell
cultur
model
find
like
due
low
ratio
amount
drug
administ
total
volum
storag
compart
physicochem
properti
cad
result
broad
tissu
bind
demonstr
high
appar
volum
distribut
drug
human
bodi
district
thu
mandatori
analyz
anim
model
efficaci
cad
order
determin
appropri
dosag
length
treatment
necessari
achiev
stabl
intracellular
concentr
requir
antivir
activ
inde
pharmacokinet
characterist
possibl
poor
penetr
specif
tissu
differ
viral
strain
andor
genet
background
studi
popul
could
explain
vivo
confirm
antivir
effici
cad
improv
deliveri
cad
approach
base
nanocarri
like
phospholipid
micel
pegyl
graphen
propos
unfortun
deliveri
system
drawback
delay
cad
releas
insid
cell
well
longerhigh
storag
compound
tissu
might
increas
risk
cad
side
effect
toxic
although
cad
typic
pharmacokinet
could
reduc
efficaci
molecul
antivir
treatment
could
use
associ
antivir
compound
especi
acut
set
well
preexposur
andor
prophylaxi
regimen
peopl
high
risk
infect
highli
pathogen
virus
context
recent
shown
combin
drug
display
synergist
effect
inhibit
ebov
replic
vitro
reduc
concentr
singl
drug
anim
model
also
import
care
evalu
potenti
advers
effect
might
associ
especi
certain
class
cad
inde
even
though
sever
cad
shown
exert
antivir
activ
vitro
alreadi
licens
mainli
treatment
cardiovascular
psychiatr
diseas
estrogen
regul
antimalari
drug
absenc
side
effect
offlabel
use
remain
critic
aspect
need
properli
address
problem
relat
cad
toxic
human
treatment
alreadi
debat
last
ebov
outbreak
west
africa
special
concern
express
use
amiodaron
clinic
trial
mainli
due
potenti
side
effect
context
mention
treatment
acut
infect
highli
pathogen
viru
requir
limit
period
cad
administr
thu
potenti
reduc
risk
side
effect
howev
aspect
need
care
investig
appropri
anim
model
clinic
trial
final
despit
cad
display
wide
rang
antivir
effect
surprisingli
report
describ
posit
effect
specif
cad
replic
certain
virus
instanc
salata
et
al
report
amiodaron
significantli
increas
enterovir
progeni
releas
infect
cell
vitro
wu
et
al
describ
increas
influenza
viru
replic
human
lung
epitheli
cell
treatment
chloroquin
klintworth
cowork
report
amiodaron
cad
affect
entri
wild
type
rabi
viru
target
cell
molecul
enhanc
entri
lentivir
particl
pseudotyp
rabi
viru
envelop
glycoprotein
nonneuron
cell
note
klintworth
studi
also
highlight
fact
although
pseudovirus
good
surrog
screen
viral
entri
inhibitor
pathogen
requir
high
contain
level
laboratori
data
base
tool
need
valid
perform
experi
correspond
wildtyp
pathogen
viru
overal
report
strongli
suggest
care
monitor
cad
effect
load
virus
could
infectcoinfect
individu
treat
compound
label
well
offlabel
applic
consid
recent
emerg
reemerg
differ
highli
pathogen
virus
around
world
make
develop
effect
antivir
one
top
public
health
prioriti
repurpos
approv
drug
treat
emerg
infect
potenti
resourc
rapidli
set
therapeut
respons
toward
broad
spectrum
pathogen
cad
repres
interest
candid
drug
repurpos
studi
request
prove
real
effect
field
infecti
diseas
treatment
addit
cad
also
provid
ration
platform
develop
new
deriv
optim
achiev
strong
suppress
viral
replic
less
side
effect
respect
parent
compound
thu
forese
famili
pharmaceut
high
potenti
especi
highli
pathogen
virus
worth
investig
also
view
virus
might
emerg
public
health
threat
near
futur
final
cad
continu
repres
use
tool
lipid
research
could
find
role
also
dissect
complex
interplay
host
cell
virus
increas
number
outbreak
due
wide
array
emerg
reemerg
highli
pathogen
virus
observ
sinc
year
specif
drug
still
avail
emergingreemerg
highli
pathogen
virus
urgent
need
new
drugsnew
approach
focal
identif
broadspectrum
antivir
target
characterist
viral
life
cycl
share
differ
virusescation
amphiphil
drug
cad
interact
differ
cellular
membran
accumul
acid
intracellular
compart
late
endosomeslysosom
thu
affect
cellular
pathwaysstructur
requir
replic
sever
virusessever
fdaapprov
drug
cad
studi
drug
repurpos
screen
discoveri
new
applic
antiviralscad
also
repres
tool
studi
viral
replic
